Abstracts Archive - Page 1433 of 2425 - ACR Meeting Abstracts

Abstract Number: 226 • 2016 ACR/ARHP Annual Meeting
Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA
Puja Khanna¹, Eskinder Tafesse², Scott Baumgartner³, Anna Walker⁴ and Robert Morlock³, ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²AstraZeneca Pharmaceuticals, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA, ⁴AstraZeneca Pharmaceuticals, Luton, United Kingdom
Background/Purpose: Less than 30% of gout patients achieve treatment targets and patients with tophi are less likely to achieve these goals than patients without tophi.…
Abstract Number: 227 • 2016 ACR/ARHP Annual Meeting
Inadequately Treated Chronic Gout As the Main Reason for Primary Gout Admission in an Urban Adult Population: Results of a Retrospective Cohort Study
Mandissa Sealey¹, Ibrahim Barry², Tanyka Sam¹, Olakanmi Awe¹ and Stuart Green³, ¹Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY, ²Internal Medicine, The Brooklyn Hospital Center, Bronx, NY, ³Internal Medicine, The Brooklyn Hospital Center, Larchmont, NY
Background/Purpose: Inadequately treated patients with chronic gout are at risk for an acute attack and many often require hospitalization. An acute attack of gout increases…
Abstract Number: 228 • 2016 ACR/ARHP Annual Meeting
Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study
Valgerdur R Sigurdardottir¹, Lennart TH Jacobsson², Panagiota Drivelegka², Anna Svärd^1,3 and Mats Dehlin², ¹Rheumatology Clinic, Falun Hospital, SE-791 82 Falun, Sweden, Falun, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Clinical Research Dalarna, Falun, Sweden
Background/Purpose: Gout is the most common form of inflammatory arthritis with a prevalence of 1.5% in our area in the age group 50-59 years. Gout…
Abstract Number: 229 • 2016 ACR/ARHP Annual Meeting
Relationship Between Patient and Disease Factors and Severity of Gout in a Real-World Population
Michael Pillinger¹, Svetlana Krasnokutsky Samuels¹, Raymond Malamet², Bruce Schechter², Douglas CA Taylor³ and Robert Morlock⁴, ¹New York University, New York, NY, ²AstraZeneca, Gaithersburg, MD, ³Ironwood Pharmaceuticals, Cambridge, MA, ⁴Ardea Biosciences, Inc., San Diego, CA
Background/Purpose : Gout is the most prominent clinical manifestation of hyperuricemia, and is the most common cause of inflammatory arthritis. The symptoms of gout (eg,…
Abstract Number: 230 • 2016 ACR/ARHP Annual Meeting
A Survey of Knowledge of Optimal Gout Management in an Academic Primary Care Setting
Stefanie Wade¹ and Micha Abeles², ¹Medicine, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, Consulting Rheumatologist, Midstate Medical Center, Meriden, CT
Background/Purpose: We reviewed previous treatment approaches for gout in patients referred to a university rheumatology practice for gout management. All patients met the 2015 American…
Abstract Number: 231 • 2016 ACR/ARHP Annual Meeting
Impact of an Educational Program for the Management of Gout Directed to Primary Care Physicians
Sandra Chinchilla¹, Irati Urionagüena¹ and Fernando Perez-Ruiz^1,2, ¹Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Baracaldo, Spain
Background/Purpose: Gout is the most frequent inflammatory arthritis in males, and therefore a common cause for consultation in both primary care and specialist settings. Despite…
Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting
Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Stuart Katz⁴, Binita Shah⁵, Irina Dektiarev⁴, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, NYU School of Medicine, New York, NY, ³Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁴Medicine/Cardiology, NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Division of Cardiology, New York, NY, ⁶Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
Abstract Number: 233 • 2016 ACR/ARHP Annual Meeting
New Cardiovascular Risk Factors Screening in Patients with Gout
Juan Carlos Ordoñez¹, Mariano Andres¹, Francisca Sivera², Loreto Carmona³, Paloma Vela^4,5, Eliseo Pascual^4,5 and Jose Antonio Bernal⁴, ¹RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ELDA, Elda, Spain, ³Instituto de Salud Musculo Esqueletica, Madrid, Spain, ⁴RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO ALICANTE, Alicante, Spain, ⁵Medicina, Universidad Miguel Hernandez, Elche, Spain
Background/Purpose: Gout is a disease triggered by the crystallization of uric acid in the joints secondary to persistent hyperuricemia, that leads to chronic inflammation. Patients…
Abstract Number: 234 • 2016 ACR/ARHP Annual Meeting
Coexistent Gout and Rheumatoid Arthritis: Comparison of Comorbidity, Autoantibodies, Disease Measures, and All-Cause Mortality
Bryant R. England^1,2, Tina D. Mahajan³, Namrata Singh⁴, Brian W Coburn³, Grant W. Cannon⁵, Gail S. Kerr⁶, Andreas Reimold⁷, Angelo L. Gaffo⁸ and Ted R Mikuls⁹, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western Iowa, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, ⁵Internal Medicine, Veterans Affairs Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁶Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC, ⁷Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁸Birmingham VA & University of Alabama at Birmingham, Birmingham, AL, ⁹Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Coexistent RA and gout were previously believed to be exceedingly rare due to several hypothesized mechanisms encompassing inhibition of crystal formation, deposition, and activation.…
Abstract Number: 235 • 2016 ACR/ARHP Annual Meeting
Concurrence of Rheumatoid Arthritis and Calcium Pyrophosphate Deposition Disease: Description of a Cohort
Viktoriya Sabchyshyn¹ and Ann K. Rosenthal^2,3, ¹Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Medicine, Clement J. Zablocki VA Medical Center, Milwaukee, WI, ³Medicine, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Calcium pyrophosphate deposition disease (CPDD) is an often un-recognized form of acute and chronic arthritis preferentially affecting the elderly. Some controversy exists about a…
Abstract Number: 236 • 2016 ACR/ARHP Annual Meeting
Intrathoracic Manifestations of IgG4-Related Disease: Findings in a Cohort Study from North America
Sian Yik Lim¹, Micheal McInnis², Zachary Wallace³, Vikram Deshpande^4,5, Sharma Amita⁶ and John H. Stone⁷, ¹Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Radiology, Cardiothoracic Imaging, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁴Pathology, Massachusetts General Hospital, Boston, MA, ⁵Department of Pathology, Massachusetts General Hospital, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA, ⁷Rheumatology Unit, Massachusetts General Hospital, Boston, MA
Background/Purpose: The intrathoracic manifestations of IgG4-related disease (IgG4-RD) have been described in only a limited number of patients. No prior studies have provided detailed descriptions…
Abstract Number: 237 • 2016 ACR/ARHP Annual Meeting
Characterization of Peripheral Lymphocyte Phenotype in Patients with IgG4-Related Disease
Satoshi Kubo¹, Shingo Nakayamada², Maiko Yoshikawa¹, Yusuke Miyazaki¹, Jidong Zhao¹, Ippei Miyagawa³, Shigeru Iwata⁴, Shintaro Hirata¹, Kazuhisa Nakano³, Kazuyoshi Saito³ and Yoshiya Tanaka⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: IgG4 related disease (IgG4-RD) is a systemic disease that is characterized by the infiltration of IgG4secreting plasma cells and effector T cells into various…
Abstract Number: 238 • 2016 ACR/ARHP Annual Meeting
Identifying Immunoglobulin G4-Related Disease in Archived Pathological Specimens
Priya Prakash¹, Faisal Saeed², Slavica Bobic³, Kirk Sperber¹, Julia Yegudin-Ash¹, Humayun Islam² and Amy Wasserman⁴, ¹Medicine-Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY, ²Pathology, New York Medical College / Westchester Medical Center, VALHALLA, NY, ³Medicine-Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, ⁴Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a recently defined entity characterized by a diffuse or mass forming inflammatory reaction rich in IgG4-positive plasma cells. Due…
Abstract Number: 239 • 2016 ACR/ARHP Annual Meeting
Malignancies in Korean Patients with Immunoglobulin G4-Related Disease
Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park and Sang-Won Lee, Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Several studies have implicated the increased risk of malignancy in patients with immunoglobulin G4-related disease (IgG4-RD). Hence, we first evaluated the risk and the…
Abstract Number: 240 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Serum Cholinesterase, Number of Organ Involvement and Fibrotic Markers in Japanese Patients with IgG4-Related Disease
Satoshi Inotani¹, Yoshinori Taniguchi², Mitsuhiro Kawano³, Natsuki Maeda⁴, Hirofumi Nishikawa⁵, Mio Matsuura⁵, Kosuke Inoue⁶, Taro Horino⁵, Shimpei Fujimoto⁵ and Yoshio Terada⁶, ¹Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ²Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ³Division of Rheumatology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, ⁴Endocrinology,Metabolism,Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ⁵Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ⁶Kochi University, Nankoku, Japan
Background/Purpose: To evaluate the relationship between serum cholinesterase (ChE) level, number of organ involvement, serum fibrotic markers and imaginational outcome in Japanese patients with IgG4-related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].